Reshape Lifesciences Q2 EPS $(1.08) Beats $(1.79) Estimate, Sales $2.25M Miss $2.61M Estimate
Portfolio Pulse from mahesh@benzinga.com
Reshape Lifesciences (NASDAQ:RSLS) reported Q2 earnings per share of $(1.08), beating the analyst consensus estimate of $(1.79) by 39.66%. However, the company's quarterly sales of $2.25 million missed the analyst consensus estimate of $2.61 million by 13.64%. This represents a 22.06% decrease in sales compared to the same period last year.
August 07, 2023 | 9:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Reshape Lifesciences reported better than expected Q2 earnings per share but missed on sales. This mixed report could lead to uncertainty in the market.
Reshape Lifesciences reported a better than expected earnings per share, which is a positive signal for investors. However, the company missed on sales, which could be a concern for investors as it indicates a decrease in revenue. This mixed report could lead to uncertainty in the market, potentially impacting the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100